Controlled trial with a monthly combination injectable contraceptive in the USA.
A monthly injectable contraceptive combining estradiol cypionate and medroxyprogesterone acetate was found to be well tolerated and effective in a phase III prospective, multicenter trial conducted in the United States. In this open-label comparison with an oral contraceptive, there were no pregnancies in the group receiving the monthly combination injectable contraceptive versus one pregnancy in those receiving the oral contraceptive. The rates of discontinuation for adverse events in the two treatment groups over the 60-week trial did not differ significantly. The majority of patients in both groups reported satisfaction with the method of contraception which they were receiving.
Shulman
L P
LP
Division of Reproductive Genetics, Department of Obstetrics and Gynecology, M/C808, University of Illinois at Chicago, 820 South Wood Street, Chicago, IL 60612-7313, USA.
D000328:Adult; D001779:Blood Coagulation Factors; D003267:Contraception; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects*; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects*; D010349:Patient Compliance; D017060:Patient Satisfaction; D011247:Pregnancy; D013997:Time Factors; D014481:United States
D001779:Blood Coagulation Factors; D003277:Contraceptives, Oral, Combined; D004958:Estradiol; C007630:estradiol 17 beta-cypionate; D017258:Medroxyprogesterone Acetate